“…However, CD147 is significantly upregulated in aggressive and chronic disease states, such as in cancers [ 67 , 68 ], atherosclerosis [ 69 ], diabetes [ 70 ], ischemic stroke [ 71 ], and chronic lung obstruction diseases [ 72 ]. Additionally, CD147 is strongly expressed on endothelial cells in the brain [ 73 ], gastrointestinal tract tissues [ 74 ], platelets [ 75 ], conjunctival tissues [ 76 ], kidney glomerular cells and podocytes [ 77 ], and cardiac pericytes [ 16 , 78 ], where it could serve a more dominant role in SARS-CoV-2 infection and mediate COVID-19-related neurological disturbance, digestive tract vascular damage, increased thrombosis, conjunctivitis, acute kidney injury, and cardiovascular disruption, respectively. Intriguingly, recent studies show that CD147 plays a functional role in facilitating SARS-CoV and SARS-CoV-2 entry [ 79 , 80 ], and antibodies against CD147 block the infection capabilities of SARS-CoV-2 [ 12 ].…”